logo
WV Legislature may be called for PEIA special session in July

WV Legislature may be called for PEIA special session in July

Yahoo05-06-2025
The Public Employees Insurance Agency is proposing increasing premiums by 14% for state employees and by 16% for local government employees during the 2026 fiscal year. (Lori Kersey | West Virginia Watch)
While West Virginia employees prepare for their health insurance to take up more of their paychecks this summer, a special session may be coming in July — the same month those increases take effect — to deal with ongoing cost and sustainability challenges at the Public Employees Insurance Agency.
At the finance board's regular meeting Thursday, Chairman Eric Householder said the agency has been working with Gov. Patrick Morrisey's office as he prepares to call the special legislative session.
'I know currently … we are working providing data to the governor,' Householder said. 'There's been no decision on what to do, just providing data, having roundtable discussions. That's all we're doing right now.'
Householder said Morrisey tentatively intends to call a special session for PEIA in mid July.
Beginning in July, PEIA premiums are increasing by 14% for state employees and by 16% for local government employees. Out-of-pocket and copay costs will also go up. The agency will also raise premiums by 12% for retirees.
PEIA leaders have said that the rising cost of health care — particularly inflation on prescription GLP-1 drugs that treat obesity and diabetes — are a major driver of the rate increases.
Union leaders and state employees have repeatedly called on the Legislature to come up with a solution to PEIA's rising costs, but the issue largely went unaddressed during the 2025 regular session.
Morrisey said in April that he plans to call a special session for PEIA, but he has not said how exactly the issue of increasing costs will be addressed..
'That was kicked down the road for many, many years,' the governor said in April. 'I don't intend to kick it down the road. We have to bring everyone together, all the stakeholders: listen, learn and then you'll be seeing some activity.'
In a news release Thursday, leadership from the West Virginia Democratic Party blamed Morrisey for 'falling to act' and letting 'devastating' PEIA increases go into effect.
'Pay-Cut Patrick failed to take action to stabilize PEIA premiums,' Democratic Party Chair Mike Pushkin said in the statement. 'So now, state employees, including law enforcement officers, school teachers, school service personnel, CPS workers, and retirees will soon be paying a price for his inaction. Morrisey had a choice — he could have fought to protect working West Virginians. Instead, he did what he always does: protect his political donors and let working families bear the burden.'
In an email Thursday, Morrisey spokesman Drew Galang said the governor has emphasized that the state 'must address the inherited challenges facing PEIA and its long term sustainability.' He said Morrisey had 'already indicated' that a special session to do so would occur in 'mid to late July.'
Galang did not respond to an email asking to clarify when, publicly, the July timeframe had been set by Morrisey and no such references to it have been made clear in previous PEIA meetings or announcements prior to Thursday.
A spokeswoman for the House of Delegates and one for the state Senate said the governor has not formally told lawmakers the special session will be in July.
Dale Lee, president of the West Virginia Education Association, told Householder the discussions about PEIA solutions should include public employees and their representatives.
'The employees can't be the ones providing all of this,' Lee said of the cost increases. 'We have to have the Legislature. There has to be not only the Legislature but also the providers. That's why I continue to ask that we all go back to the table and that we come up with a plan that people can agree on.'
Lee, who has repeatedly criticized state leaders for failing to act on the recommendations of a task force called by former Gov. Jim Justice after statewide teacher strikes in 2018 and 2019, said it's important that the Legislature act upon a plan for PEIA this time.
'[It] never even got on a committee agenda,' he said of the recommendations. 'That's just disingenuous.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

West Virginia athletic department agrees to partnership with local mulch company
West Virginia athletic department agrees to partnership with local mulch company

USA Today

time30 minutes ago

  • USA Today

West Virginia athletic department agrees to partnership with local mulch company

On the same day Kansas received a record-breaking $300 million donation, one of the Jayhawks' Big 12 counterparts secured a deal of its own. West Virginia has agreed to a multi-year partnership with Grant County Mulch that makes the company the official mulch supplier of the Mountaineers' athletic department, the university announced August 13. Based in Petersburg, West Virginia, about 90 miles southeast of West Virginia's Morgantown campus, Grant County Mulch is the largest bulk mulch supplier in the country, according to the Mountaineers' release. As part of the newly inked and undeniably unique agreement — after all, how many colleges have an official mulch supplier? — Grant County Mulch will be racing a West Virginia-themed truck in the NASCAR Craftsman Truck Series at the Richmond Raceway in Virginia on August 15. The truck is owned by CR7 Motorsports and will be driven by Grant Enfinger. Beyond the company's logo being displayed on LED boards at football and basketball games, as well as on the outfield wall at baseball games, the Mountaineers' post-game radio show for football and men's basketball will award a 'Tough as Mulch' player of the game. Financial terms of the deal were not disclosed. "Both of us — and our parents — were born and raised in West Virginia, so this partnership means more than business to us," Larry and Janie Berg, founders of Grant County Mulch, said in a statement. "It's about honoring our roots, supporting our home state, and being part of something that represents the pride and spirit of West Virginians everywhere."

Popular weight-loss drugs linked to sudden vision loss, research suggests
Popular weight-loss drugs linked to sudden vision loss, research suggests

Yahoo

time2 hours ago

  • Yahoo

Popular weight-loss drugs linked to sudden vision loss, research suggests

New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss. Two studies, published in JAMA, analyzed how semaglutide and tirzepatide — which include popular drugs like Ozempic, Wegovy, Mounjaro and Zepbound — impacted eye health in Americans with type 2 diabetes over a two-year period. One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN) – a rare eye condition that can lead to sudden vision loss due to lack of blood flow – in association with semaglutide and tirzepatide. Popular Weight-loss Medication Could Relieve Painful Arthritis Symptoms, Doctors Report Out of more than 159,000 study participants with type 2 diabetes, 35 developed NAION, compared to 19 people in the comparison group. The Ohio-based researchers also noted an increased risk of developing "other optic nerve disorders," identified in 93 patients. Read On The Fox News App Although the second study did not observe a "statistically significant difference" in NAION in GLP-1 drug users, there was a small increase in diabetic retinopathy, an eye disease that can damage the retina. Diabetic Patients Taking Glp-1s May Face Increased Risk Of Eye Disease, Study Suggests While individuals with type 2 diabetes on GLP-1s showed a modestly increased risk of diabetic retinopathy, the researchers concluded that fewer patients experienced sight-threatening complications from the disease. "These findings suggest that all patients with type 2 diabetes treated with GLP-1 RAs, regardless of preexisting diabetic retinopathy, should be regularly screened and monitored for potential complications," the study authors concluded. Sue Decotiis, M.D., a medical weight loss doctor in New York City, said she believes more studies are required to confirm the association between these drugs and vision loss, as these studies report some conflicting results. "NAION is a rare condition of the optic nerve that, although serious, has not really been shown to be increased by these studies," Decotiis, who was not involved in the research, told Fox News Digital. "We need more studies for certain." Diabetic patients already face a high incidence of eye disease related to blood flow and nerve damage, the expert noted. "Eye complications are often directly related to the degree or lack thereof of diabetes control." Click Here To Sign Up For Our Health Newsletter In most cases, GLP-1 drugs reduce the severity of type 2 diabetes, therefore reducing the incidence of eye diseases, Decotiis noted. These drugs have also been shown to reduce the risk of cardiovascular disease, like hypertension, and to improve circulation, which can improve eye health. For diabetics who are starting a GLP-1, Decotiis recommends having an exam done by an ophthalmologist and scheduling follow-up exams throughout treatment. "We should take precaution with methodical ophthalmic care for diabetics on these drugs," Decotiis said. "However, let's not throw the baby out with the bath water." For more Health articles, visit Novo Nordisk, maker of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital. "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously. NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels in the U.S." "Novo Nordisk, on its part, has conducted an analysis across randomized controlled clinical trials with GLP-1 receptor agonists, including a blinded ophthalmologist evaluation to confirm NAION diagnoses. Our current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and NAION events."Original article source: Popular weight-loss drugs linked to sudden vision loss, research suggests Solve the daily Crossword

Alligator Bioscience to Host Virtual R&D Day on 19 August 2025
Alligator Bioscience to Host Virtual R&D Day on 19 August 2025

Yahoo

time3 hours ago

  • Yahoo

Alligator Bioscience to Host Virtual R&D Day on 19 August 2025

LUND, SE / / August 14, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that it will host a virtual R&D Day on Tuesday, 19 August 2025 at 4 p.m. CEST. The event will provide an in-depth update on Alligator's R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1-15 September 2025). During the event, members of Alligator's executive management and R&D leadership will: Provide update on mitazalimab clinical data, as well biomarker findings and Phase 3 readiness. Discuss ongoing and planned investigator-initiated trials (IITs) exploring mitazalimab in additional indications and clinical settings. Provide a brief update on the pipeline program HLX22. Outline key R&D milestones over the next 6-12 months. The R&D Day will be held as a live Teams webinar and will include a Q&A session. All participants will have the opportunity to submit questions in advance, via ir@ or during the event. Event detailsDate: Tuesday, 19 August 2025Time: 4-5 p.m. CESTFormat: Virtual Teams webinarRegistration: Please use this link to register A replay of the event will be made available on Alligator's website after the webinar. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 1:00 p.m. CEST on 14 August 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit Attachments Alligator Bioscience to host virtual R&D Day on 19 August 2025 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store